An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age.

Trial Profile

An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2015

At a glance

  • Drugs Doripenem (Primary)
  • Indications Gram-negative infections; Gram-positive infections; Intra-abdominal infections; Nosocomial pneumonia; Respiratory tract infections; Urinary tract infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 15 Jun 2012 Actual patient number 52 added as reported by ClinicalTrials.gov.
    • 18 May 2012 Actual end date Apr 2012 added as reported by ClinicalTrials.gov.
    • 18 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top